SNPs in 3′ UTR miRNA target sequences associated with individual drug susceptibility

E Rykova, N Ershov, I Damarov… - International Journal of …, 2022 - mdpi.com
The complementary interaction of microRNAs (miRNAs) with their binding sites in the 3′
untranslated regions (3′ UTRs) of target gene mRNAs represses translation, playing a …

[HTML][HTML] Insights into the critical role of the PXR in preventing carcinogenesis and chemotherapeutic drug resistance

X Niu, T Wu, G Li, X Gu, Y Tian… - International Journal of …, 2022 - ncbi.nlm.nih.gov
Pregnane x receptor (PXR) as a nuclear receptor is well-established in drug metabolism,
however, it has pleiotropic functions in regulating inflammatory responses, glucose …

Pregnane X receptor (PXR) polymorphisms and cancer treatment

A Skandalaki, P Sarantis, S Theocharis - Biomolecules, 2021 - mdpi.com
Pregnane X Receptor (PXR) belongs to the nuclear receptors' superfamily and mainly
functions as a xenobiotic sensor activated by a variety of ligands. PXR is widely expressed …

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?

A Maslarinou, VG Manolopoulos… - Frontiers in Pharmacology, 2023 - frontiersin.org
Fluoropyrimidines are chemotherapeutic agents widely used for the treatment of various
solid tumors. Commonly prescribed FPs include 5-fluorouracil (5-FU) and its oral prodrugs …

Intestine-specific FXR agonists as potential therapeutic agents for colorectal cancer

Y Yin, M Wang, W Gu, L Chen - Biochemical Pharmacology, 2021 - Elsevier
Colorectal cancer (CRC) is one of the most malignant cancers in the world. A major cause of
death in CRC patients is the limited therapeutic options in its advanced stages. The …

IL15RA and SMAD3 genetic variants predict overall survival in metastatic colorectal cancer patients treated with folfiri therapy: A new paradigm

E De Mattia, J Polesel, R Roncato, A Labriet… - Cancers, 2021 - mdpi.com
Simple Summary There is an increasing scientific interest in the study of the interaction
between the immune system and drugs in cancer that can affect the efficacy of an anti …

Pharmacogenetics role of genetic variants in immune-related factors: A systematic review focusing on mCRC

L Scarabel, A Bignucolo, G Toffoli, E Cecchin… - Pharmaceutics, 2022 - mdpi.com
Pharmacogenetics plays a key role in personalized cancer treatment. Currently, the clinically
available pharmacogenetic markers for metastatic colorectal cancer (mCRC) are in genes …

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients

P Riera, D Páez - Expert Opinion on Drug Metabolism & …, 2021 - Taylor & Francis
Introduction Irinotecan is a cytotoxic agent that is widely used in the treatment of several
types of solid tumors. However, although it is generally well tolerated, approximately 20% to …

Germline and somatic pharmacogenomics to refine rectal cancer patients selection for neo-adjuvant chemoradiotherapy

E De Mattia, R Roncato, E Palazzari, G Toffoli… - Frontiers in …, 2020 - frontiersin.org
Neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery is the standard of care
for patients with Locally Advanced Rectal Cancer (LARC). Current selection for nCRT is …

Unlocking the Potential: FKK6 as a Microbial Mimicry-Based Therapy for Chronic Inflammation-Associated Colorectal Cancer in a Murine Model

L Sladekova, H Li, VM DesMarais, AP Beck… - The Journal of …, 2024 - Elsevier
Chronic intestinal inflammation significantly contributes to the development of colorectal
cancer and remains a pertinent clinical challenge, necessitating novel therapeutic …